Publication: Noncoding RNA in drug resistant sarcoma
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Impact Journals LLC
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Li, Xiaoyang, Jacson K. Shen, Francis J. Hornicek, Tao Xiao, and Zhenfeng Duan. 2017. “Noncoding RNA in drug resistant sarcoma.” Oncotarget 8 (40): 69086-69104. doi:10.18632/oncotarget.19029. http://dx.doi.org/10.18632/oncotarget.19029.
Research Data
Abstract
Sarcomas are a group of malignant tumors that arise from mesenchymal origin. Despite significant development of multidisciplinary treatments for sarcoma, survival rates have reached a plateau. Chemotherapy has been extensively used for sarcoma treatment; however, the development of drug resistance is a major obstacle limiting the success of many anticancer agents. Sarcoma biology has traditionally focused on genomic and epigenomic deregulation of protein-coding genes to identify the therapeutic potential for reversing drug resistance. New and more creative approaches have found the involvement of noncoding RNAs, including microRNAs and long noncoding RNAs in drug resistant sarcoma. In this review, we discuss the current knowledge of noncoding RNAs characteristics and the regulated genes involved in drug resistant sarcoma, and focus on their therapeutic potential in the future.
Description
Other Available Sources
Keywords
noncoding RNA (ncRNA), microRNA (miR), long noncoding RNA (lncRNA), drug resistance, sarcoma
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service